Cambridge Healthtech Institute’s Inaugural
Digital Health: Pharmaceutical Executive Summit
Driving Innovation in Digital Therapeutics, Clinical Trials, and Healthcare
June 18-19, 2019
Digital Health is promising to revolutionize healthcare delivery, optimize personalized and precision medicine, and offer new tools for drug and diagnostic development. The applications of biosensors, mobile devices and wearables, Internet of Things,
mobile health platforms, artificial intelligence, and digital biomarkers are quickly expanding into all areas of patient monitoring and disease management, point-of-care diagnostics, and digital endpoints in clinical trials. Cambridge Healthtech Institute’s
Inaugural Digital Health: Pharmaceutical Executive Summit will bring together leading experts and thought leaders in digital health to discuss the latest technologies and implementation of digital tools into drug development, diagnostics
and healthcare.
Final Agenda
Day 1 | Day 2 | Download Brochure | Speaker Biographies
Tuesday, June 18
7:00 am Registration Open and Morning Coffee
8:00 Chairperson’s Remarks
Joris Van Dam, PhD, Head, Digital Therapeutics, Novartis Institutes for BioMedical Research
8:10 KEYNOTE PRESENTATION: Digital Therapeutics in Pharma
Joris Van Dam,
PhD, Head, Digital Therapeutics, Novartis Institutes for BioMedical Research
Digital Therapeutics represent a novel treatment modality, where high-quality, clinically validated software applications are used for the prevention, management or treatment of disease. We will review some of our key experiences from our partnership
with Pear Therapeutics that was announced in March 2018: What is the unmet need that can be addressed? What are potential synergies between digital- and pharmacotherapies? How can a large pharma organization best adopt digital therapeutics?
8:40 The Rise of Digital Therapeutics as Companions to Existing and Future Therapies
Pierre
Leurent, CEO, Voluntis
Digital therapeutics (DTx) represent a new class of solutions that have the potential to improve patients’ treatment experience, by enhancing the efficacy and/or safety of medications. Case studies will illustrate how these solutions are
currently developed and commercialized in different therapeutic areas. Future development scenarios will be explored, including the advent of drug/DTx combination therapies.
9:10 Digital Therapeutics - A New 'Pill'ar in Big Pharma
Joel Sangerman, Chief Commercial Officer, Click Therapeutics
The largest pharmaceutical companies in the world are tapping digital therapeutics companies as investors and as commercial partners in bids to treat patients with software apps as stand-alone therapies and as companions to their drugs. Hear how traditional pharma commercialization models compare with those for digital therapeutics and how payers plan to cover, reimburse, and use digital therapeutics in medical policies and prior authorization criteria for drug coverage.
9:40 Grand Opening Coffee Break in the Exhibit Hall with Poster Viewing
10:25 Attend concurrent session
10:55 Supporting Patient Journey through Medication Management
Omri Shor, CEO & Co-Founder, Medisafe
11:25 PANEL DISCUSSION: Future of Digital Therapeutics
Moderator: Joris Van Dam, PhD, Head, Digital Therapeutics, Novartis Institutes for BioMedical Research
Panelists:
Pierre Leurent, CEO, Voluntis
Joel Sangerman, Chief Commercial Officer, Click Therapeutics
Discussion topics include:
- What are the emerging business models for digital therapeutics?
- How are big pharma impacted by digital therapeutics?
- What are the unmet technology needs?
11:55 Transition to Lunch
12:00 pm Enjoy Lunch on Your Own
12:30 Session Break
1:05 Chairperson’s Remarks
Mohanad Fors, MBA, Co-Founder, Global Head of Biome - The Digital Innovation Lab by Novartis
1:10 Virtual Clinical Trials, Empowering Patients and Create 20k Trial
Mohanad
Fors, MBA, Co-Founder, Global Head of Biome - The Digital Innovation Lab by Novartis
This talk will share the new landscape of the digital health ecosystem and the important role of technology to disrupt how pharma works, touching one of the key critical topics in pharma which is clinical trials and empowering the patients
as part of our role in supporting the ecosystem and the patients.
1:40 KEYNOTE PRESENTATION: Principles for Transforming Clinical Trials with Digital Medicine
Peter Bergethon, MD, FAAN, FANA, Vice President and Head, Digital and Quantitative Medicine, Biogen, Inc.
2:10 The Brave New World of Voice and Chatbots: How AI-Driven Virtual Assistants Improve Pharma Brand Engagement and Rx Adherence
Nathan Treloar, President & Co-Founder, Orbita
Discover why leading pharma brands are seizing the power of voice- and chatbot-powered experiences. Whether delivered via smart speakers (Amazon Echo, Google Home, etc.) or via web, mobile or other devices, virtual assistants are now leveraging
conversational AI to provide FAQs, Rx support, just-in-time interventions, triaged call center escalation, and other solutions to boost patient engagement, medication adherence and brand loyalty. Demand is rising for this consumer-friendly
approach not only by millennials, but also by older adults who are widely adopting new tools and technology.
2:25 Refreshment Break in the Exhibit Hall with Poster Viewing
3:10 Making Trials More Attractive, Inclusive and Manageable with Innovative Use of Connected Devices: Case Studies and Lessons Learned from a Big Pharma Company
Bert Hartog,
PhD, Senior Director, Clinical Innovation, Janssen Pharmaceutica N.V.
Clinical trials are notoriously difficult to execute. Finding the right people to participate and motivating them to stay in the trial are significant challenges for study sponsors and sites. Innovative use of connected devices can be a gamechanger,
reducing the trial burden, integrating trials into people’s daily lives and collecting more granular data. Use cases will be presented to show how to make this happen in a big pharma environment.
3:40 A Platform Approach to Real-World Evidence and Real-World Population Health Transformation
Ashish Atreja, MD, MPH, Chief Innovation Officer, Icahn School of Medicine at Mount Sinai
The practice of medicine is exponentially evolving. This evolution is fueled by value-based transformation and incentives that are aligning for continuous, proactive care, within and outside the four walls of the hospitals. To address this
need, the new generation of startups is leveraging disciplines like data science, informatics, digital medicine, genomics, and AI; but this is creating a problem of plenty. In spite of more than 350,000 mobile apps for healthcare, less
than 4% of patients are recommended apps by providers today.
4:10 PANEL DISCUSSION: Digital Tools in Clinical Trials
Moderator: Mohanad Fors, MBA, Co-Founder, Global Head of Biome - The Digital Innovation Lab by Novartis
Panelists:
Ashish Atreja, MD, MPH, Chief Innovation Officer, Icahn School of Medicine at Mount Sinai
Peter Bergethon, MD, FAAN, FANA, Vice President and Head, Digital and Quantitative Medicine, Biogen, Inc.
Bert Hartog, PhD, Senior Director, Clinical Innovation, Janssen Pharmaceutica N.V.
Jamileh Jemison, MS, MD, Head of Clinical Development, HealthMode
Discussion topics include:
- How can digital technologies transform clinical trials?
- What are strategies to incorporate digital tools in clinical development?
- What are technology development needs? What areas require increased investment?
- What are the barriers to adoption of digital tools in big pharma and how to overcome them?
5:20 Taste of New England Welcome Reception in the Exhibit Hall with Poster Viewing
5:25 Meet the Plenary Keynotes
6:25 Find Your Table, Meet Your Moderator
6:30 Breakout Discussion Groups
7:30 Close of Day
Day 1 | Day 2 | Download Brochure | Speaker Biographies
Wednesday, June 19
7:00 am Registration Open and Morning Coffee
8:00 Chairperson’s Remarks
Tomasz Adamusiak, MD, PhD, Director Medical Informatics Lead, Digital Medicine & Translational Imaging, Pfizer
8:05 Digital Health Opportunities 2025
Raj Pallapothu, mHealth Global Lead, Bayer
8:35 Breakthrough Digital – Making a Positive Impact on Millions of Patients
Adrian Chernoff, MBA, Former Worldwide Vice President, Global Head of Research and Development, Johnson and Johnson
It’s not every day a breakthrough product is created. From idea to market, we will cover the R&D journey in delivering digital transformation at scale at Johnson & Johnson. The result is the #1 diabetes app in the U.S. and
Canada with over one million downloads. We will cover the multi-faceted dynamics of developing a breakthrough digital at scale inclusive of customer experience, putting the patient at the center, big data, agile vs. waterfall, IoT,
cloud, data privacy, intelligent medical devices and remote patient monitoring.
9:05 Presentation to be Announced
9:35 Coffee Break in the Exhibit Hall with Poster Viewing
10:05 Poster Winner Announced
10:20 Building a Digital Health Data Pipeline in the Cloud
Tomasz Adamusiak, MD, PhD, Director Medical Informatics Lead, Digital Medicine & Translational Imaging, Pfizer
The mission of the Digital Medicine group and the Pfizer Innovation Research (PfIRe) Lab is to solve key business problems using dynamical measures and advanced STEM platforms. Our goal is to utilize digital remote monitoring of patients’
symptoms to develop and validate novel clinical endpoints for disease diagnosis and health state assessment. This presentation will explore the unique challenges of digital biomarkers from a data engineering and knowledge management
perspective.
10:50 Humanizing Care through AI
Kamal Jethwani, MD, MPH, Senior Director, Pivot Labs, Partners HealthCare; Assistant Professor, Harvard Medical School
Health systems and healthcare industries are eagerly diving into AI and machine learning technologies, allocating significant resources toward validating and refining predictive algorithms for a range of applications, including diagnostic
tools and aids to clinical decision making. However, we need to understand the human users of these algorithms, and how their clinical workflows, decisions, and relationships with patients will be affected, and how best to position
AI for success in the delivery of care.
11:20 Precision Healthcare through Multi-Scale Biomedical Data Integration
Jessilyn
Pearl Dunn, PhD, Assistant Professor, Biomedical Engineering and Biostatistics & Bioinformatics, Duke University
Recent technological advancements make it possible to closely and continuously monitor individuals on multiple scales in real time while also incorporating genetic, environmental, and lifestyle information. We are collecting and using
this multi-scale biomedical data to gain a more precise understanding of health and disease at molecular and physiological levels and developing actionable, predictive health models for improving cardiometabolic outcomes.
11:50 Transition to Lunch
12:00 pm Enjoy Lunch on Your Own
12:30 Transition to Plenary
12:50 PLENARY KEYNOTE SESSION
2:20 Booth Crawl and Dessert Break in the Exhibit Hall with Poster Viewing
2:25 Meet the Plenary Keynotes
3:05 Close of Conference
Day 1 | Day 2 | Download Brochure | Speaker Biographies
Stay on to attend Wednesday, June 19 - Thursday, June 20
Digital Biomarkers: Biosensors, Wearables, and mHealth